P-gp efflux has no impact on dose proportionalty of Digoxin bioavailability over a dose range of 0.125 to 1.5mg: The outcome of a new PBPK model, that includes the in vitro transporter information is consistent with the clinical observations

Amin Rostami-Hochaghan; S Neuhoff; Yeo K Rowland; M Jamei; A Rostami-Hodjegan

P-gp efflux has no impact on dose proportionalty of Digoxin bioavailability over a dose range of 0.125 to 1.5mg: The outcome of a new PBPK model, that includes the in vitro transporter information is consistent with the clinical observations

Amin Rostami-Hochaghan, S Neuhoff, Yeo K Rowland, M Jamei, A Rostami-Hodjegan

Research output: Contribution to conference › Poster

Original language	English
Publication status	Published - Oct 2011
Event	13th Annual Congress for Clinical Pharmacology, Zurich, Switzerland - 13th Annual Congress for Clinical Pharmacology, Zurich, Switzerland Duration: 20 Oct 2011 → 22 Oct 2011

Conference

Conference	13th Annual Congress for Clinical Pharmacology, Zurich, Switzerland
City	13th Annual Congress for Clinical Pharmacology, Zurich, Switzerland
Period	20/10/11 → 22/10/11

Cite this

Rostami-Hochaghan, A., Neuhoff, S., Rowland, Y. K., Jamei, M., & Rostami-Hodjegan, A. (2011). P-gp efflux has no impact on dose proportionalty of Digoxin bioavailability over a dose range of 0.125 to 1.5mg: The outcome of a new PBPK model, that includes the in vitro transporter information is consistent with the clinical observations. Poster session presented at 13th Annual Congress for Clinical Pharmacology, Zurich, Switzerland, 13th Annual Congress for Clinical Pharmacology, Zurich, Switzerland.

Rostami-Hochaghan, Amin ; Neuhoff, S ; Rowland, Yeo K et al. / P-gp efflux has no impact on dose proportionalty of Digoxin bioavailability over a dose range of 0.125 to 1.5mg: The outcome of a new PBPK model, that includes the in vitro transporter information is consistent with the clinical observations. Poster session presented at 13th Annual Congress for Clinical Pharmacology, Zurich, Switzerland, 13th Annual Congress for Clinical Pharmacology, Zurich, Switzerland.

@conference{e201b24493b345d7bb098a02a7895684,

title = "P-gp efflux has no impact on dose proportionalty of Digoxin bioavailability over a dose range of 0.125 to 1.5mg: The outcome of a new PBPK model, that includes the in vitro transporter information is consistent with the clinical observations",

author = "Amin Rostami-Hochaghan and S Neuhoff and Rowland, {Yeo K} and M Jamei and A Rostami-Hodjegan",

year = "2011",

month = oct,

language = "English",

note = "13th Annual Congress for Clinical Pharmacology, Zurich, Switzerland ; Conference date: 20-10-2011 Through 22-10-2011",

}

Rostami-Hochaghan, A, Neuhoff, S, Rowland, YK, Jamei, M & Rostami-Hodjegan, A 2011, 'P-gp efflux has no impact on dose proportionalty of Digoxin bioavailability over a dose range of 0.125 to 1.5mg: The outcome of a new PBPK model, that includes the in vitro transporter information is consistent with the clinical observations', 13th Annual Congress for Clinical Pharmacology, Zurich, Switzerland, 13th Annual Congress for Clinical Pharmacology, Zurich, Switzerland, 20/10/11 - 22/10/11.

P-gp efflux has no impact on dose proportionalty of Digoxin bioavailability over a dose range of 0.125 to 1.5mg: The outcome of a new PBPK model, that includes the in vitro transporter information is consistent with the clinical observations. / Rostami-Hochaghan, Amin; Neuhoff, S; Rowland, Yeo K et al.
2011. Poster session presented at 13th Annual Congress for Clinical Pharmacology, Zurich, Switzerland, 13th Annual Congress for Clinical Pharmacology, Zurich, Switzerland.

Research output: Contribution to conference › Poster

TY - CONF

T1 - P-gp efflux has no impact on dose proportionalty of Digoxin bioavailability over a dose range of 0.125 to 1.5mg: The outcome of a new PBPK model, that includes the in vitro transporter information is consistent with the clinical observations

AU - Rostami-Hochaghan, Amin

AU - Neuhoff, S

AU - Rowland, Yeo K

AU - Jamei, M

AU - Rostami-Hodjegan, A

PY - 2011/10

Y1 - 2011/10

M3 - Poster

T2 - 13th Annual Congress for Clinical Pharmacology, Zurich, Switzerland

Y2 - 20 October 2011 through 22 October 2011

ER -

Rostami-Hochaghan A, Neuhoff S, Rowland YK, Jamei M, Rostami-Hodjegan A. P-gp efflux has no impact on dose proportionalty of Digoxin bioavailability over a dose range of 0.125 to 1.5mg: The outcome of a new PBPK model, that includes the in vitro transporter information is consistent with the clinical observations. 2011. Poster session presented at 13th Annual Congress for Clinical Pharmacology, Zurich, Switzerland, 13th Annual Congress for Clinical Pharmacology, Zurich, Switzerland.